Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.240
-0.030 (-1.32%)
At close: Apr 28, 2026, 4:00 PM EDT
2.290
+0.050 (2.23%)
After-hours: Apr 28, 2026, 7:39 PM EDT
Fortress Biotech Revenue
In the year 2025, Fortress Biotech had annual revenue of $63.26M with 9.69% growth. Fortress Biotech had revenue of $16.08M in the quarter ending December 31, 2025, with 6.34% growth.
Revenue (ttm)
$63.26M
Revenue Growth
+9.69%
P/S Ratio
1.14
Revenue / Employee
$811,051
Employees
78
Market Cap
72.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.26M | 5.59M | 9.69% |
| Dec 31, 2024 | 57.68M | -26.84M | -31.76% |
| Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
| Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
| Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionFBIO News
- 7 days ago - Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ - GlobeNewsWire
- 4 weeks ago - Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 weeks ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 4 weeks ago - Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 5 weeks ago - Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewsWire
- 2 months ago - UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 2 months ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 2 months ago - Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease - GlobeNewsWire